Abstract
Because of the relative resistance of chronic myeloid leukemia (CML) progenitors to most standard cytotoxic agents, marrow-ablative doses of drugs or radiotherapy followed by allogeneic bone marrow transplantation (BMT) remain the only curative option for patients with CML. However, the effectiveness of allogeneic BMT is limited by the toxicity of graft-versus-host disease and the lack of histocompatible donors for most patients. Although it avoids these major obstacles of allogeneic BMT, autologous BMT has not been effective in CML because of the inability to purge CML from the autologous graft and the absence of the allogeneic immunologic antitumor activity. Techniques that allow the clinical isolation of normal stem cells from CML marrow combined with novel posttransplantation immunotherapeutic approaches should make autologous BMT a curative treatment for CML in the near future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
